Longitudinal Assessment of COVID-19 Vaccine Uptake: A two-wave survey of a nationally representative U.S. sample

Principal Investigator(s):  View help for Principal Investigator(s) Caroline Katzman, Columbia University Medical Center; Tucker Morgan, Columbia University. Mailman School of Public Health; Ariel de Roche, Columbia University Medical Center; Julen Harris, Columbia University Medical Center; Christine Mauro, Columbia University. Mailman School of Public Health; Gregory Zimet, Indiana University. School of Medicine; Susan Rosenthal, Columbia University Medical Center

Version:  View help for Version V1

Name File Type Size Last Modified
horizontal.sas7bdat application/x-sas-data 6 MB 09/20/2023 05:18:AM
longitudinal_logistic_regs.sas application/x-sas 8.8 KB 09/20/2023 05:26:AM
longitudinal_weighted_frequencies.sas application/x-sas 5.5 KB 11/02/2022 10:46:AM

Project Citation: 

Katzman, Caroline, Morgan, Tucker, de Roche, Ariel, Harris, Julen , Mauro, Christine, Zimet, Gregory, and Rosenthal, Susan. Longitudinal Assessment of COVID-19 Vaccine Uptake: A two-wave survey of a nationally representative U.S. sample. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2023-09-20. https://doi.org/10.3886/E193927V1

Project Description

Summary:  View help for Summary Understanding factors that influence those who are initially COVID-19 vaccine hesitant to accept vaccination is valuable for the development of vaccine promotion strategies. Using Ipsos KnowledgePanel®, we conducted a national survey of adults aged 18 and older in the United States. We created a questionnaire to examine factors associated with COVID-19 vaccine uptake over a longitudinal period (“Wave 1” in April 2021 and “Wave 2” in February 2022), and utilized weighted data provided by Ipsos to make the data nationally representative. Overall, 1189 individuals participated in the Wave 1 survey, and 843 participants completed the Wave 2 survey (71.6% retention rate). Those who intended to be vaccinated as soon as possible (“ASAP”) were overwhelmingly vaccinated by Wave 2 (96%, 95% CI: 92% to 100%). Of those who initially wished to delay vaccination until there was more experience with it (“Wait and See”), 57% (95% CI: 47% to 67%)  were vaccinated at Wave 2. Within the “Wait and See” cohort, those with income <$50,000 and those who had never received the influenza vaccine were significantly less likely to be vaccinated at Wave 2. Among those who initially indicated that they would not receive a COVID-19 vaccine (“Non-Acceptors”), 28% (95% CI: 21% to 36%)  were vaccinated at Wave 2. Those who believed COVID-19 was not a major problem in their community were significantly less likely to be vaccinated, while those with more favorable attitudes toward vaccines in general and public health strategies to decrease the impact of COVID-19 were significantly more likely to be vaccinated. Overall, barriers to vaccine uptake for the “Wait and See” cohort appear to be more practical, whereas barriers for the “Non-Acceptor” cohort seem to be more ideological. These findings will help target interventions to improve uptake of COVID-19 boosters and future novel vaccines.
Funding Sources:  View help for Funding Sources Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp



Related Publications

Download this project

Published Versions

V1 [2023-09-20]

Export Metadata

Dublin Core

DDI 2.5

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as received from the data depositor. As of April 2026, depositors are required to submit study materials in accessible formats. ICPSR has not reviewed, checked, or processed this material. For additional information about the study, please contact the investigator(s) directly. If you have questions about the accessibility of materials distributed by ICPSR or require further assistance, please visit ICPSR's Accessibility Center.